Global Pericarditis Market Growth (Status and Outlook) 2023-2029

Global Pericarditis Market Growth (Status and Outlook) 2023-2029

Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It is typically better sitting up and worse with lying down or breathing deep. Other symptoms may include fever, weakness, palpitations, and shortness of breath. Occasionally onset of symptoms is gradual.

LPI (LP Information)' newest research report, the “Pericarditis Industry Forecast” looks at past sales and reviews total world Pericarditis sales in 2022, providing a comprehensive analysis by region and market sector of projected Pericarditis sales for 2023 through 2029. With Pericarditis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pericarditis industry.

This Insight Report provides a comprehensive analysis of the global Pericarditis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pericarditis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pericarditis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pericarditis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pericarditis.

The global Pericarditis market size is projected to grow from US$ 1918.2 million in 2022 to US$ 2640 million in 2029; it is expected to grow at a CAGR of 4.7% from 2023 to 2029.

Treatment in most cases is with NSAIDs and possibly colchicine. Steroids may be used if those are not appropriate. Typically symptoms improve in a few days to weeks but can occasionally last months. Complications can include cardiac tamponade, myocarditis, and constrictive pericarditis. It is a less common cause of chest pain. About 3 per 10,000 people are affected per year. Those most commonly affected are males between the ages of 20 and 50. Up to 30% of those affected have more than one episode.

This report presents a comprehensive overview, market shares, and growth opportunities of Pericarditis market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Acute Pericarditis
Chronic Pericarditis
Recurrent Pericarditis

Segmentation by application
Hospitals & Clinics
Medical Institutes
Research Organization

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Astrazeneca
Bayer
Reckitt Benckiser
Perkinelmer
Fujifilm
Merck Sharp & Dohme
Allergan

Please note: The report will take approximately 2 business days to prepare and deliver.